



- ☐ A: Continue 3-weekly platinum-based chemotherapy with PARP-i
- ☐ B: Continue 3-weekly platinum-based chemotherapy without PARP-i
- ☐ C: Switch to weekly platinum-based chemotherapy without PARP-i
- ☐ D: Switch chemotherapy
- ☐ E: Add bevacizumab to systemic therapy
- ☐ F: Plan an interval CRS
- ☐ G: Consider treatment in clinical trials
- ☐ H: Stop all systemic therapy and switch to best supportive care

Patient 1: WHO 1, HRD positive, 75 years; Patient 2: WHO 3, HRD negative, 85 years

HGS: high grade serous; CRS: cytoreductive surgery, PARP-i: poly ADP-ribose polymerase inhibitors, HRD: homologous recombination deficiency

Figure 2: Treatment strategies